Validate Novel Pathways
Discover Predictive Biomarkers
Optimize Clinical Strategy

27 EXPERT SPEAKERS INCLUDE:

Michael Giordano
SVP, Oncology
Bristol-Myers Squibb

Roy Baynes
SVP, Immuno-oncology
Merck

Ho Cho
Executive Director, Biotherapeutics
Celgene

Edward Cha
Associate Medical Director
Genentech

Robert Hofmeister
VP, Translational Immunotherapy
EMD Serono

Sponsored by:
WELCOME TO IMMUNE CHECKPOINT INHIBITORS

BENEFITS OF ATTENDING

Realizing the Next Generation of Immune Checkpoint Inhibitors

The Immune Checkpoint Inhibitors meeting will enable you to enhance the clinical performance of your immuno-oncology pipeline. Designed with input from Merck, BMS, Genentech, Novartis, EMD Serono, and Amgen, this industry forum will crack the roadblocks limiting further progress in the field.

The meeting will help you to effectively validate novel pathways, discover clinically predictive biomarkers and optimize clinical strategy. Meet and engage with the industry experts who are progressing new ICI drugs and propel your own research forward.

Access industry intelligence on how to:

- Differentiate yourself from the competition by exploring novel checkpoint pathways
- Maximize patient response through identifying and validating clinically predictive biomarkers
- Improve efficacy and speed to market by determining which combination strategies are of highest priority
- Overcome technical challenges of monitoring and predicting immune response
- Investigate immune competent models so you can effectively translate into the clinic
- Accelerate translational drug progress by optimizing your clinical trial design
- Discover how to capitalize on market potential by hearing talks on successfully implemented launch strategies

Join us at Immune Checkpoint Inhibitors for what will be the single greatest pool of insights and experiences within ICIs. Without doubt the most valuable 3 days of your year.

WHAT MAKES IMMUNE CHECKPOINT INHIBITORS SPECIAL?

FOCUSED CONTENT: Concentrating only on immune checkpoint modulation means we dig into a much greater depth of content and discussion. Leave bursting with insights, ideas and solutions.

IMPORTANT TOPICS: From research with BMS, Merck, AstraZeneca and other drug developers the agenda topics reflect the most pressing challenges of today and tomorrow. Covering everything from the validation of novel pathways to preclinical models and clinical combos.

EXPERT INDIVIDUALS: Immune Checkpoint Inhibitors will bring together thought-leaders across pharma, biotech and academia who are pioneering the development of new immune checkpoint drugs. Learn, network and benchmark with these individuals to find solutions and establish new partnerships.

HEAR WHAT PREVIOUS HANSON WADE ATTENDEES HAVE TO SAY:

- Strong program, great speakers and a genuine focus on identifying solutions. — Novartis

- It exceeded my expectations. The talks were high quality and the interaction among participants was excellent. — Genentech

- I think that Hanson Wade put on a very professional, scientific, well organized and pleasant meeting that encouraged positive networking. I loved the speed networking and workshops. — Merck

CONTENTS

Meet the Speakers: 3
Review The Agenda Day 1: 4
Review The Agenda Day 2: 5
Review The Workshops: 6
See Who Attends & How Networking Works: 7
The Venue & Pricing Options: 8
### SPEAKERS

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roy Baynes</td>
<td>SVP, Immuno-oncology</td>
<td>Merck</td>
</tr>
<tr>
<td>Vahe Bedian</td>
<td>Director, Oncology</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Yannick Bulliard</td>
<td>Principal Investigator, Oncology Pharmacology</td>
<td>Amgen</td>
</tr>
<tr>
<td>Edward Cha</td>
<td>Associate Medical Director</td>
<td>Genentech</td>
</tr>
<tr>
<td>Ho Cho</td>
<td>Executive Director, Biotherapeutics</td>
<td>Celgene</td>
</tr>
<tr>
<td>Simon Dovedi</td>
<td>Institute for Cancer Sciences</td>
<td>University of Manchester</td>
</tr>
<tr>
<td>Gordon Freeman</td>
<td>Associate Professor, Medicine</td>
<td>Harvard Medical School</td>
</tr>
<tr>
<td>Michael Giordano</td>
<td>SVP, Oncology</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Leon Hall</td>
<td>Senior Director, Global Scientific Development and Translational</td>
<td>Taconic Biosciences</td>
</tr>
<tr>
<td>Fiona Harding</td>
<td>Senior Principal Research Scientist, Biotherapeutics</td>
<td>Abbvie</td>
</tr>
<tr>
<td>Mary Lynne Hedley</td>
<td>COO</td>
<td>TESARO</td>
</tr>
<tr>
<td>Robert Hofmeister</td>
<td>VP, Translational Immunotherapy</td>
<td>EMD Serono</td>
</tr>
<tr>
<td>Rick Huntress</td>
<td>Senior Manager Business Development</td>
<td>The Jackson Laboratory</td>
</tr>
<tr>
<td>Jeff Hutchins</td>
<td>VP, Preclinical Research</td>
<td>Peregrine Pharmaceuticals</td>
</tr>
<tr>
<td>Bahija Jallal</td>
<td>VP</td>
<td>MedImmune</td>
</tr>
<tr>
<td>Sylvia Janetzki</td>
<td>President</td>
<td>Zellnet Consulting</td>
</tr>
<tr>
<td>Jennifer Mataraza</td>
<td>Principal Investigator, Oncology Biotherapeutics</td>
<td>Novartis</td>
</tr>
<tr>
<td>Cokey Nguyen</td>
<td>VP, Research and Development</td>
<td>Enumeral</td>
</tr>
<tr>
<td>Alexandre Passiukov</td>
<td>VP, Translational Medicine</td>
<td>Pierre-Fabre</td>
</tr>
<tr>
<td>Paul Rennert</td>
<td>Founder &amp; Principal</td>
<td>SugarCone Biotech Consultants</td>
</tr>
<tr>
<td>Tibor Keler</td>
<td>CSO</td>
<td>CellDex</td>
</tr>
<tr>
<td>Jeffrey Schlam</td>
<td>Chief, Laboratory of Tumor Immunology and Biology</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Giovanni Selvaggi</td>
<td>VP, Clinical Development</td>
<td>OncoLytics</td>
</tr>
<tr>
<td>Marc Theoret</td>
<td>Lead Medical Officer, Melanoma/Sarcoma Group</td>
<td>FDA</td>
</tr>
<tr>
<td>Derek Wainwright</td>
<td>Assistant Professor, Department of Neurological Surgery</td>
<td>Northwestern University</td>
</tr>
<tr>
<td>Bas Van Der Woning</td>
<td>Senior Scientist</td>
<td>arGEN-X</td>
</tr>
<tr>
<td>Cassian Yee</td>
<td>Professor, Department of Melanoma Medical Oncology</td>
<td>MD Anderson Cancer Center</td>
</tr>
</tbody>
</table>

**Very invigorating conference! Bringing a group of like minded people together to share common stories.**

Eli Lilly

**A very informative and interesting conference.**

AstraZeneca
CONFERENCE DAY 1 - WEDNESDAY, MARCH 25TH

8.50 Chair Opening Remarks
Ho Cho, Executive Director, Celgene

9.00 The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field
- Discuss how checkpoint antibodies have changed the way we think about & treat cancer (focus on CTLA-4 & PD-1)
- Identify the critical issues facing the development of cancer immunotherapies & how we can overcome these issues
- Discuss the importance of collaboration between industry, academia, regulators, payers & advocacy groups to advance cancer immunotherapies
Michael Giordano, SVP, Oncology, Bristol-Myers Squibb

9.30 Speed Networking & Morning Refreshments
A revolutionary & highly valuable way to meet fellow attendees in a 60 minute session. Bring lots of business cards!

Develop Combination Strategies

11.00 Keynote: Advancing Immune Checkpoint Inhibitors At Merck
- Review of the development of Pembrolizumab for malignant melanoma
- Efficacy in multiple solid tumors
- Optimizing monotherapy & exploration of combination therapy
Roy Baynes, SVP, Immuno-oncology, Merck

11.30 Expansion And Activation Of T-Cells Via The Targeting Of The Immunosuppressive Ligand Phosphatidylserine: Combination Strategy With Other Checkpoint Inhibitors
- Demonstrate how phosphatidylserine (PS) is externalized in the tumor microenvironment upon apoptosis
- Establish that the antibody-mediated blockade of PS signaling breaks immune tolerance, reactivates immunity, resulting in durable anti-tumor responses in multiple preclinical models
- Review how combination studies of PS-targeting antibodies in immune competent models with anti-PD-1 and anti-CTLA-4
Jeff Hutchins, VP, Preclinical Research, Peregrine Pharmaceuticals

12.00 Personalized Cancer Immunotherapy Combinations
- Understand the biology behind immunotherapy combinations with checkpoint inhibitors
- Explore strategies to determine optimal combinations
- Discuss a paradigm of tailoring combination therapies to an individual's immune response
Edward Cha, Associate Medical Director, Genentech

12.30 Title TBC
Cassian Yee, Professor, Department of Melanoma Medical Oncology, MD Anderson Cancer Center

1.00 Up-regulation Of PDI And PD-L1 In Solid Tumors Upon Treatment With Reolysin, An Oncolytic Virus
Giovanni Selvaggi, VP, Clinical Development, Oncolytics

1.10 Lunch

2.15 Coordinating Immune Checkpoint Blockades For Cancer Immunotherapy In Combination
- Checkpoint inhibitors in combination
- Combinations with targeted therapies
- The future: combos with CARTs, bispecifics
Jennifer Mataraza, Principal Investigator, Oncology Biotherapeutics, Novartis

Harness Clinically Relevant Immunogenic Tumor Models

2.45 Case Study: Immunocompetent Mouse Models For Tumor Immunology Applications
- Considerations for selecting surrogate mAbs for immuno-oncology studies
- Immunocompetent murine tumor models: selection of models and interpretation of results
Fiona Harding, Senior Principal Research Scientist, Biotherapeutics, Abbvie

3.15 Preclinical And Clinical Evidence For CD70 & Validation Of Novel Checkpoint Target GARP
- Investigate preclinical & clinical data for novel checkpoint pathway CD70
- In vivo efficacy of novel immune checkpoint target GARP, in GVHD mouse model with human PBMCs
Bas Van Der Woning, Senior Scientist, arGEN-X

3.45 Patient Derived Xenografts In Humanized (cd34+) NSG Mice – Immuno-oncology Efficacy Testing
- Treatment of tumor bearing mice with both traditional SOC drugs and checkpoint inhibitors
- Overview of the differences in tumor growth rate, SOC response and immune modulation as a component of preclinical drug efficacy testing
Rick Huntress, Senior Manager Business Development, The Jackson Laboratory

4.15 Networking & Afternoon Refreshments

Optimize Clinical Strategy

4.45 Interrogating Weaknesses Of Glioblastoma: Immune Checkpoints Take Center Stage
- In the context of treatment with immune checkpoint blockade-based therapies, efforts aimed at proactively identifying responders vs. non-responders will be discussed
- Understanding the caveats of translating current preclinical findings to patients, as well as the design of new and/or improved immunotherapeutic modalities with decreased toxicities
Derek Wainwright, Assistant Professor, Department of Neurological Surgery, Northwestern University

5.15 Translational Strategy To Validate Patient Relevance Of Innovative Drug Combinations With Immune Checkpoint Ligands
Alexandre Passioukov, VP, Translational Medicine, Pierre-Fabre

5.45 Chair’s Closing Remarks
CONFERENCE DAY 2 - THURSDAY, MARCH 26TH

7.45 Breakfast Briefing: Humanized Immune System Mice For Immuno-Oncology Applications
Leon Hall, Senior Director, Global Scientific Development and Translational Discovery Services, Taconic Biosciences

8.50 Chair Opening Remarks
Mary Lynne Hedley, COO, TESARO

9.00 Keynote: Clinical Impact Of Checkpoint Inhibitors As Novel Cancer Therapies
- Understand the relevance of checkpoint molecules in cancer indications
- Discover how safety profile & molecular mechanisms will impact the design of combination studies & the development of biomarkers
Robert Hofmeister, VP, Translational Immunotherapy, EMD Serono

9.30 Title TBC
Marc Theoret, Lead Medical Officer, Melanoma/Sarcoma Group, FDA

10.00 Finding Translational Biomarkers That Aid Patient Selection

10.30 Mastermind Session
Take part in this unique collaborative brainstorming session. Attendees will pool their collective knowledge at the meeting to generate new understanding. Gain access to the perspectives of multiple stakeholders and together predict future trends and industry challenges.

11.00 Networking & Morning Refreshments

11.30 Antibodies To Checkpoint Regulators Mediate Intratumoral T-Cell Depletion & Anti-tumor Efficacy Via FcgR Receptors
- Engagement of activating FcgR receptors is required for the anti-tumor efficacy of antibodies targeting CTLA4, OX40 & GITR
- Selective depletion of intratumoral T-cells expressing high levels of CTLA-4, OX40 & GITR correlates with anti-tumor efficacy
- Antibody-mediated depletion of intratumoral regulatory &/or exhausted T-cells may provide therapeutic benefit in human cancer
Yannick Bulliard, Principal Investigator, Oncology Pharmacology, Amgen

12.00 Understanding Mechanisms Of Resistance To Immune Checkpoint Inhibition
- Appreciate the diversity of immune functions that immune checkpoints regulate
- Enhance anti-tumor immunity at multiple levels

12.30 Physiologic Target Validation On Immune Effector Cells
Cokey Nguyen, VP Research and Development, Enumeral

12.40 Lunch

1.45 Novel Target Pathways Which Promote Immune Response
- Explore costimulatory signals in the development of an immune response
Gordon Freeman, Associate Professor, Medicine, Harvard Medical School

2.15 Evaluation Of An Agonist Anti-CD27 Human Antibody (Varililumab) & Its Potential For Combination With Checkpoint Inhibitors
- Introduction to CD27 as an important immune booster
- Review of Phase I clinical data for Varililumab
- Review of preclinical data supporting combination of Varililumab with checkpoint inhibitors
- Combination clinical trials of Varililumab with checkpoint inhibitors
Tibor Keler, CSO, Celldex

2.45 Networking & Afternoon Refreshments

3.15 Manipulation of the Immune Response to Radiation Therapy: Unlocking the Potential
- Efficacy of radiotherapy can be improved by modulation of the host immune response
- Generate effective anti-cancer immune response
- Explore anti-PD1, PDL-1 mAb & TLR7 agonists combination therapies
Simon Dovedi, Institute for Cancer Sciences, University of Manchester

3.45 Future Strategies For Market Success

3.45 What’s The Future Hold For ICIs? Cross Industry Perspectives
- Lessons learned from progress in the field so far
- Will ICIs work in all indications or are other drugs needed?
- How do different stakeholders need to contribute?
Panellists:
Tibor Keler, CSO, Celldex
Yannick Bulliard, Principal Investigator, Oncology Pharmacology, Amgen
Derek Wainwright, Assistant Professor, Department of Neurological Surgery, Northwestern University
Vahe Bedian, Director, Oncology External Projects, AstraZeneca

4.15 Chair’s Closing Remarks & Close Of Conference
**PRE CONFERENCE WORKSHOP A**

**Review of Immune Checkpoint Inhibitors & the New Oncology Landscape**

**Date:** Tuesday March 24th **Time:** 8.30am-11.30am

This workshop will provide a valuable overview of the current state of the art in the field as well as thoughts on future industry trends.

**Attend this workshop and gain:**
- Lessons learned from the clinical development & marketization of Yervoy, Opdivo & Keytruda
- An evaluation of immunotherapy landscape & immune checkpoint inhibitors
- Exciting case studies on the biggest scientific innovations in immune checkpoint inhibition

Leave with ideas on what the next 10 years hold for immune checkpoint modulation.

---

**Workshop leader**

**Paul Rennert**

Founder & Principal

**SugarCone Biotech Consultants**

Paul is the founder of SugarCone Biotech LLC, a consulting firm specializing in the oncology, immunology, and autoimmunity therapeutic areas. He has authored numerous publications and patents, has given lectures world-wide on diverse topics including his own research, the biotechnology industry, drug development strategy and the emergence of immune checkpoint biology and immuno-oncology.

**PRE CONFERENCE WORKSHOP B**

**How Can We Monitor Patients Consistently: Overcoming Technical Challenges in Monitoring Immune Responses**

**Date:** Tuesday March 24th **Time:** 12.00pm-3.00pm

The workshop will deliver insights on three main topics:
- Strategies on obtaining patient samples
- Efforts to conserve sample integrity
- Tools for reliable immune monitoring assay performance

Benefit from addressing specific topics including obtaining blood and tissue samples; processing, storage and transport of samples; tools to preserve stability and functionality of samples; defining a reliable and precise assay; accuracy in immune monitoring; what to look for when considering to involve a CRO in sample management and/or assay performance.

---

**Workshop leader**

**Sylvia Janetzki**

President

**ZellNet Consulting**

The focus of Sylvia’s work at ZellNet Consulting during the past 16 years has been immune monitoring approaches for clinical studies with specific focus on Elispot and sample integrity. Her work has also led her to a tight collaboration with the Cancer Immunotherapy Consortium (CIC/CRI), for which she initiated and lead a proficiency panel program addressing different assays like Elispot, Multimer staining, ICS, Luminex and others.

---

"Very useful – combined the delivery of cutting edge research with an opportunity to network. I normally go to major scientific meetings and have always been sceptical that smaller meetings like this could add anything useful – I have been proved wrong!"

_Aquila_
NETWORKING
IMMUNE CHECKPOINT INHIBITORS

SPEED NETWORKING
A structured networking session - run like speed dating - especially designed to facilitate quick introductions to the majority of attendees. Use the time wisely to meet new contacts and reconnect with old friends.

ROUND TABLE DISCUSSIONS
Take part in facilitated discussion sessions focused around specific, high priority issues. Discuss your experiences and observations within focus groups then share your and the other groups’ finding with the main conference.

STRUCTURED NETWORKING BREAKS
In between the formal presentations the networking carries on. Use the multiple refreshment and lunch breaks to continue your discussions in an informal relaxed atmosphere.

YOU’LL MEET PEOPLE FROM...

INDUSTRY BREAKDOWN

- Pharma: 34%
- Biotech: 15%
- Academic: 11%
- CRO: 13%
- Platform Tech: 8%
- Other: 5%

SENIORITY BREAKDOWN

- C-level: 32%
- VP: 23%
- Director: 37%
- Scientist: 8%

Highly interactive meeting with a right balance between opportunities to meet the other participants and the many interesting presentations.

Ablynx

Great speakers, great networking, great and stimulating discussions!

Sanofi

SUPPORTING PARTNERS

QUICK FIRE FIGURES

Predicted annualized growth rate of 24.1% 25 drugs in clinical trials 3 market authorized products
**VENUE AND ACCOMMODATION:**

Venue: Just a stone’s throw away from the Commons, our boutique hotel takes inspiration from the city’s rich history while reveling in the unpredictable. Each space at Revere Hotel complements the next, allowing you to create your own unique and original Boston experience. Explore a completely new side of the city at our luxury hotel in Boston.

Hotel name
Revere Hotel Boston Common
200 Stuart Street
Boston MA 02116
United States
www.reverehotel.com

Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering.

**REGISTER**

www.immune-checkpoint.com/register
Tel: +1 212 537 5898
Email: register@hansonwade.com
Mail: Hanson Wade
4th Floor, 52 Grosvenor Gardens, London, SW1W BAU

**TEAM DISCOUNTS**

• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

**TERMS & CONDITIONS**

Full payment is due on registration. Cancellations and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W BAU

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

* All discount offers (including team discounts) require payment at the time of registration to receive any discount. Early Bird discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.